spacer
home > epc > winter 2003 > editor's letter
PUBLICATIONS
European Pharmaceutical Contractor

Editor's Letter

Welcome to the latest edition of EPC - winter seems to have appeared very suddenly!

I am pleased that we have a keynote article in this issue from Trevor Jones of the Association of the British Pharmaceutical Industry, in which he highlights issues of importance to the whole industry. The article considers the World Trade Organization's deal concerning the provision of generic drugs in less developed areas of the world. He highlights how industry works in partnership with public organisations to find ways to treat diseases in those areas. He also emphasises that it is not just the provision of treatments which is important - there needs to be an adequate infrastructure to ensure that diseases are efficiently diagnosed and then treated.


Partnerships designed to solve health problems are also identified in an article from John Savopoulos of Datamonitor that looks back to the outbreak of SARS earlier this year. Industry mounted a quick response to this threat, and again there are instances of public bodies providing support to corporate efforts. The outbreak was effectively managed by isolation and containment to prevent its spread, and this highlights how important diagnosis of disease can be. A valuable immediate contribution of industry has been the development of a diagnostic allowing differentiation of SARS infected patients from those with other viral diseases such as flu - this can quickly contribute to the isolation and containment effort.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Julia Lloyd-Parks
spacer
Julia Lloyd-Parks
spacer
spacer
spacer
John White
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement